Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 149 Show results per page	View Search Criteria \| Help With Results


1.		Phase II/III Randomized Study of Two Dose Levels of Epirubicin vs ADR in Patients with Disseminated Carcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								BGSM-74484 NCI-V85-0227


2.		Phase II/III Comparison of Single-agent Chemotherapy with Idarubicin vs Menogaril vs 4'-Epiadriamycin vs Standard Chemotherapy with CAV (CTX/ADR/VCR) in Patients with Extensive Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI				EST-1586


3.		Phase II/III Randomized Study of Two Dose Levels of Epirubicin vs ADR in Patients with Disseminated Carcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								NYH-068004-087 NCI-V86-0129


4.		Phase II/III Randomized Study of Two Dose Levels of Epirubicin vs ADR in Patients with Disseminated Carcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								YALE-HIC-3709 NCI-V86-0094

Last Modified: 4/12/2007


5.		Phase II Evaluation of IPP, CBDCA, CHIP, and epi-ADR as Single Agents Prior to Phase III Randomized Comparison of CECA (CACP/VP-16/CTX/ADR) vs High-Dose CACP/VP-16/CTX/ADR in Children Aged at Least 365 Days with Previously Untreated Stage D Neuroblastoma and Phase III Multimodal Treatment of Stage C Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				1 to 21				NCI				POG-8741/42 POG-8741, POG-8742

Last Modified: 7/1/1988


6.		Phase II Evaluation of the Efficacy of Short-term Intensive Intravesicular EPI-ADR for Ablation of a Postoperative Residual Marker Lesion in Patients with Multiple Superficial Bladder Cancer and Phase III Comparison of Maintenance with Intravesicular EPI-ADR vs No Maintenance (Summary Last Modified 07/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				85 and under								EORTC-30869

Last Modified: 7/20/2007


7.		Phase II/III Randomized Comparison of DOX vs Two Schedules of High-Dose Epirubicin in Patients with Advanced Soft Tissue Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 70								EORTC-62901

Last Modified: 12/17/2007 First Published: 12/1/1993


8.		Phase III Randomized Study of Tamoxifen vs Placebo in Women with Node-Positive or High Risk Node-Negative Breast Cancer Who Have Completed Adjuvant Combination Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				pre-/perimenopausal								CAN-NCIC-MA12 NCI-V93-0323, NCT00002542, MA12

Last Modified: 3/1/1994


9.		Phase III Randomized Study of Short-Term, Intensive Adjuvant Chemotherapy with 5-FU/EPI/CTX After Radical Local Treatment in Women with Isolated Locoregional Relapse of Breast Cancer (Summary Last Modified 03/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				any age								EORTC-10920

Last Modified: 11/1/1997


10.		Phase III Randomized Study of EPI vs MITO Administered at Standard vs High Dose Following TUR for First Recurrence or First Diagnosis of Multiple Tumors in Superficial Bladder Cancer (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				no age specified								MRC-BS07 EU-94028

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute